NASDAQ: LIPOLipella Pharmaceuticals Inc Stock
$0.71+0.00 (+0%)
Updated Apr 26, 2024
LIPO Price
$0.71
Fair Value Price
-$0.14
Market Cap
$4.44M
52 Week Low
$0.64
52 Week High
$2.71
P/E
-0.92x
P/B
1.41x
P/S
13.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$449.62k
Earnings
-$4.62M
Gross Margin
100%
Operating Margin
-1,024.9%
Profit Margin
-1,027.3%
Debt to Equity
0.14
Operating Cash Flow
-$3M
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LIPO Overview
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LIPO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LIPO ($0.71) is overvalued by 595.24% relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LIPO ($0.71) is not significantly undervalued (595.24%) relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LIPO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LIPO due diligence checks available for Premium users.
Be the first to know about important LIPO news, forecast changes, insider trades & much more!
LIPO News
Valuation
LIPO fair value
Fair Value of LIPO stock based on Discounted Cash Flow (DCF)
Price
$0.71
Fair Value
-$0.14
Undervalued by
594.55%
LIPO ($0.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LIPO ($0.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LIPO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LIPO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.92x
Industry
14.88x
Market
41.14x
LIPO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.41x
Industry
5.85x
LIPO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LIPO's financial health
Profit margin
Revenue
$120.8k
Net Income
-$688.9k
Profit Margin
-570.1%
LIPO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LIPO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.6M
Liabilities
$432.7k
Debt to equity
0.14
LIPO's short-term assets ($3.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIPO's short-term assets ($3.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIPO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$727.7k
Investing
$0.0
Financing
$1.6M
LIPO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LIPO vs Biotech Stocks
Lipella Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.